Immunogenicity and safety of influenza vaccination in 3- to 6-year-old children with a two dose immunisation schedule

Hoecke, C. Van; Raue, W.; Künzel, W; Engelmann, H.

doi:10.1007/bf02002729

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 60 eligible articles published between 1987 and 2006 describing inactivated seasonal influenza vaccine immunogenicity studies conducted in the United States, Canada, Europe, Israel, and Russia 10 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 . We included 129 independent study arms of which 119 reported data on response to A/H1N1, 109 on influenza B, and 108 on A/H3N2 vaccine strains (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…We identified 60 eligible articles published between 1987 and 2006 describing inactivated seasonal influenza vaccine immunogenicity studies conducted in the United States, Canada, Europe, Israel, and Russia 10,22–80 . We included 129 independent study arms of which 119 reported data on response to A/H1N1, 109 on influenza B, and 108 on A/H3N2 vaccine strains (Table 1).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Seidman

Richard

Viboud

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

Please cite this paper as: Seidman et al. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6(1), 52–62. Background Seasonal influenza epidemics are associated with significant morbidity and mortality each year, particularly amongst young children and the elderly. Seasonal influenza vaccines have been available for decades, yet influenza remains a major public health threat in the US, sparking interest in studies evaluating the effectiveness of vaccination. Objectives We sought to identify determinants of serological responses to inactivated seasonal influenza vaccines including number of doses, adjuvant, and subject characteristics. Methods We reviewed 60 articles published between 1987 and 2006. We used weighted multiple logistic regression and random‐effects models to evaluate how seroconversion and seroprotection rates varied with host and vaccine factors. Results Both children and seniors tended to have poorer immune responses compared to adults whereas use of adjuvant and a second vaccine dose tended to improve immune response. Pre‐vaccination serological status had a large impact on the immune response to vaccination. We found substantial heterogeneity among studies, even with similar population settings and vaccination regimen. Conclusions Future studies should stratify their results by pre‐vaccination serological status in an effort to produce more precise summary estimates of vaccine response.

show abstract

Section: Resultsmentioning

confidence: 99%

“…We identified 60 eligible articles published between 1987 and 2006 describing inactivated seasonal influenza vaccine immunogenicity studies conducted in the United States, Canada, Europe, Israel, and Russia 10,22–80 . We included 129 independent study arms of which 119 reported data on response to A/H1N1, 109 on influenza B, and 108 on A/H3N2 vaccine strains (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Quantitative review of antibody response to inactivated seasonal influenza vaccines

Seidman

Richard

Viboud

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…the proportion of vaccinees with haemagglutination inhibiting antibody titres ³1:40) [5] were similar for both split and subunit vaccines (v 2 0.94; P < 0.625). For this reason the data were pooled.…”

mentioning

confidence: 83%

“…Recently, Van Hoecke C et coll. [5] published data concerning the immunogenicity of in¯uenza vaccine containing 15 lg HA in a mixed group of primed and unprimed (i.e. undetectable inhibiting antibody titres at baseline) 3±6-year-old children.…”

mentioning

confidence: 98%